MCID: IND016
MIFTS: 19

Indolent B-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Indolent B-Cell Non-Hodgkin Lymphoma

MalaCards integrated aliases for Indolent B-Cell Non-Hodgkin Lymphoma:

Name: Indolent B-Cell Non-Hodgkin Lymphoma 58
Indolent B-Cell Nhl 58

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Orphanet 58 ORPHA300842

Summaries for Indolent B-Cell Non-Hodgkin Lymphoma

MalaCards based summary : Indolent B-Cell Non-Hodgkin Lymphoma, also known as indolent b-cell nhl, is related to lymphoma, hodgkin, classic and lymphoma, non-hodgkin, familial. The drugs rituximab and ofatumumab have been mentioned in the context of this disorder. Affiliated tissues include t cells.

Related Diseases for Indolent B-Cell Non-Hodgkin Lymphoma

Diseases related to Indolent B-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 26)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 10.9
2 b-cell non-hodgkin lymphoma 10.9
3 lymphoma, hodgkin, classic 10.9
4 neutropenia 10.8
5 lymphoma 10.7
6 follicular lymphoma 10.7
7 mantle cell lymphoma 10.6
8 b-cell lymphoma 10.5
9 leukemia, chronic lymphocytic 10.4
10 lymphopenia 10.4
11 nodal marginal zone lymphoma 10.4
12 indolent b cell lymphoma 10.2
13 liver cirrhosis 10.2
14 retinitis 10.2
15 agammaglobulinemia 10.2
16 constipation 10.2
17 hepatitis b 10.2
18 hepatitis c 10.2
19 thrombocytopenia 10.2
20 neuroretinitis 10.2
21 marginal zone b-cell lymphoma 10.2
22 lymphoplasmacytic lymphoma 10.2
23 exanthem 10.2
24 myelodysplastic syndrome 10.2
25 leukemia, acute myeloid 10.2
26 lymphoma, mucosa-associated lymphoid type 10.2

Graphical network of the top 20 diseases related to Indolent B-Cell Non-Hodgkin Lymphoma:



Diseases related to Indolent B-Cell Non-Hodgkin Lymphoma

Symptoms & Phenotypes for Indolent B-Cell Non-Hodgkin Lymphoma

Drugs & Therapeutics for Indolent B-Cell Non-Hodgkin Lymphoma

Drugs for Indolent B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3 174722-31-7 10201696
2
ofatumumab Approved Phase 3 679818-59-8 6918251
3 Antineoplastic Agents, Immunological Phase 3
4 Immunologic Factors Phase 3
5 Antirheumatic Agents Phase 3
6 Antibodies Phase 3
7 Immunoglobulins Phase 3
8 Antibodies, Monoclonal Phase 3
9 Alkylating Agents Phase 3
10 Bendamustine Hydrochloride Phase 3
11 Pharmaceutical Solutions Phase 3
12
Idelalisib Approved Phase 2 870281-82-6
13
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
14
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
15
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
16
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
17
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
18
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
19
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
20
Ledipasvir Approved Phase 2 1256388-51-8 67505836
21 Bryostatin 1 Investigational Phase 2 83314-01-6
22 Adjuvants, Immunologic Phase 2
23 Histone Deacetylase Inhibitors Phase 2
24 Immunosuppressive Agents Phase 2
25 Nitrogen Mustard Compounds Phase 2
26 Anti-Infective Agents Phase 2
27 Antiviral Agents Phase 2
28 Hepatitis C Antibodies Phase 2
29 Ledipasvir, sofosbuvir drug combination Phase 2
30
Chlorambucil Approved Phase 1 305-03-3 2708
31
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
32
Bortezomib Approved, Investigational Phase 1 179324-69-7 93860 387447
33
Lenalidomide Approved Phase 1 191732-72-6 216326
34
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
35 Angiogenesis Inhibitors Phase 1
36 Antimetabolites Phase 1

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
2 A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3 Active, not recruiting NCT02367040 Phase 3 Copanlisib (BAY 80-6946);Placebo;Rituximab
3 Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy Terminated NCT01200589 Phase 3
4 Randomized Open Label of Ofatumumab and Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment Terminated NCT01077518 Phase 3 Ofatumumab;Bendamustine infusion;Ofatumumab and Bendamustine infusions (Arm A);Bendamustine infusion (Arm B)
5 A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab Terminated NCT01289223 Phase 3 Bendamustine IV
6 A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection in Subjects With Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas Completed NCT04569838 Phase 2 Bendamustine hydrochloride injection
7 A Phase II Trial Of Bryostatin-1 In Combination With Rituximab In Rituximab-Refractory Indolent B-cell Non Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia Completed NCT00087425 Phase 2 bryostatin 1
8 A Phase II Open-label Study of SH L 749 in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphomas Completed NCT00220285 Phase 2 Zevalin (SH L 749 , BAY86-5128);Zevalin (SH L 749 , BAY86-5128)
9 A Randomized, Multicenter, Phase II Evaluation of ONTAK (Denileukin Diftitox) in Patients With Previously Treated, Indolent, B-Cell, Non-Hodgkin's Lymphoma Completed NCT00051025 Phase 2 ONTAK
10 An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) Completed NCT01108341 Phase 2 Bendamustine hydrochloride;Ofatumumab
11 Phase II Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-label Study) Completed NCT00612183 Phase 2 bendamustine hydrochloride
12 A Phase II Study of MK-0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Completed NCT00875056 Phase 2 Vorinostat
13 A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed After Rituximab or a Rituximab Containing Therapy Completed NCT01294579 Phase 2 Bendamustine
14 A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphomas Refractory to Rituximab and Alkylating Agents Completed NCT01282424 Phase 2 Idelalisib
15 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcYRIIB), in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab Recruiting NCT03571568 Phase 1, Phase 2
16 A Japanese Phase 2 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Recruiting NCT04533581 Phase 2 ME-401
17 A Phase 2, Open-label, Single Arm, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 (Lisocabtagene Maraleucel) in Adult Subjects With High-risk, Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) Recruiting NCT04245839 Phase 2 Fludarabine;Cyclophosphamide;JCAR017
18 Bendamustine + Obinutuzumab Induction Chemoimmunotherapy With Risk-adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma Recruiting NCT03311126 Phase 2 Bendamustine;Obinutuzumab
19 A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma Active, not recruiting NCT02086175 Phase 2 Imprime PGG;Rituximab
20 A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma Active, not recruiting NCT02207062 Phase 2 Ibrutinib
21 Open-label, Uncontrolled, Single-arm, Phase Ib/II Study of Intravenous Copanlisib in Japanese Patients With Indolent B-cell Non Hodgkin's Lymphomas Relapsed After or Refractory to Standard Therapy Active, not recruiting NCT02342665 Phase 1, Phase 2 Copanlisib (BAY80-6946)
22 A Pilot Phase II Study of New Direct-Acting Antiviral Agent, HARVONI® (Ledipasvir/Sofosbuvir), for the Treatment of Genotype 1 or 2 HCV-Associated Indolent B-Cell Non- Hodgkin's Lymphoma Not yet recruiting NCT03261349 Phase 2 Ledipasvir and sofosbuvir
23 A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab Terminated NCT02384954 Phase 1, Phase 2
24 Phase I Trial to Assess the Safety and Pharmacokinetics of GP2013 Monotherapy Administered Weekly in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma Completed NCT01933516 Phase 1 GP2013
25 A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Completed NCT01088048 Phase 1 Idelalisib;Rituximab;Bendamustine;Ofatumumab;Fludarabine;Everolimus;Bortezomib;Chlorambucil;Lenalidomide
26 A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Completed NCT01410513 Phase 1 SAR245409
27 The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma Completed NCT00271050 Phase 1
28 A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia Completed NCT02242045 Phase 1 Idelalisib
29 An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma Completed NCT01691807 Phase 1 ofatumumab;bendamustine
30 A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma Recruiting NCT04578600 Phase 1 Lenalidomide;Oral Azacitidine
31 A Japanese Phase 1 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Active, not recruiting NCT03985189 Phase 1 ME-401
32 Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Completed NCT02072967

Search NIH Clinical Center for Indolent B-Cell Non-Hodgkin Lymphoma

Genetic Tests for Indolent B-Cell Non-Hodgkin Lymphoma

Anatomical Context for Indolent B-Cell Non-Hodgkin Lymphoma

MalaCards organs/tissues related to Indolent B-Cell Non-Hodgkin Lymphoma:

40
T Cells

Publications for Indolent B-Cell Non-Hodgkin Lymphoma

Articles related to Indolent B-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 93)
# Title Authors PMID Year
1
Histologic Transformation in an Untreated Waldenstrom's Macroglobulinemia After 14 Years: Case Report and Review of the Literature. 61
33643507 2021
2
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. 61
32856068 2020
3
Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. 61
32529585 2020
4
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. 61
32810220 2020
5
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result. 61
31838764 2020
6
Where does transplant fit in the age of targeted therapies? 61
31808860 2019
7
Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. 61
31640581 2019
8
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. 61
31127456 2019
9
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. 61
30693983 2019
10
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. 61
30938714 2019
11
MALT Lymphoma as a Model of Chronic Inflammation-Induced Gastric Tumor Development. 61
31123886 2019
12
Burden of illness of follicular lymphoma and marginal zone lymphoma. 61
30315345 2019
13
A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. 61
29233743 2018
14
T follicular helper cells: a potential therapeutic target in follicular lymphoma. 61
29340116 2017
15
Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation. 61
28561902 2017
16
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. 61
27900638 2017
17
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate. 61
27587710 2017
18
Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. 61
27896571 2017
19
Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. 61
27714587 2016
20
B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains. 61
27750045 2016
21
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. 61
27293194 2016
22
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. 61
27101934 2016
23
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. 61
25111959 2015
24
Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation. 61
26390162 2015
25
Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. 61
26498442 2015
26
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. 61
26282650 2015
27
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. 61
25712458 2015
28
Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma. 61
26006703 2015
29
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. 61
25783753 2015
30
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. 61
26687959 2015
31
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. 61
25630297 2015
32
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. 61
25596263 2015
33
Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. 61
26196236 2015
34
Progression and Transformation of Clonally Heterogeneous B-cell Lymphoma. 61
26068800 2015
35
Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. 61
25963431 2015
36
Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas. 61
25511319 2015
37
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. 61
24927856 2014
38
Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT. 61
23996464 2014
39
[Metabolic activity measured by ¹⁸F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype]. 61
25511487 2014
40
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. 61
24617454 2014
41
Simultaneous determination of bendamustine and its active metabolite, gamma-hydroxy-bendamustine in human plasma and urine using HPLC-fluorescence detector: application to a pharmacokinetic study in Chinese cancer patients. 61
24793082 2014
42
Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. 61
24333758 2014
43
Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands. 61
24038025 2014
44
Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). 61
24870874 2014
45
microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virus. 61
25236768 2014
46
Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series. 61
24060287 2013
47
Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma. 61
23652586 2013
48
Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors. 61
23797978 2013
49
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 61
23246162 2013
50
Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China. 61
22430608 2012

Variations for Indolent B-Cell Non-Hodgkin Lymphoma

Expression for Indolent B-Cell Non-Hodgkin Lymphoma

Search GEO for disease gene expression data for Indolent B-Cell Non-Hodgkin Lymphoma.

Pathways for Indolent B-Cell Non-Hodgkin Lymphoma

GO Terms for Indolent B-Cell Non-Hodgkin Lymphoma

Sources for Indolent B-Cell Non-Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....